Breaking News
Get 40% Off 0
🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For Free Copy Portfolio
Close

Pharma Reaserch Products Co Ltd (214450)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
146,100 +5000    +3.54%
31/05 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7214450009 
  • Volume: 229,392
  • Bid/Ask: 146,100 / 146,200
  • Day's Range: 137,600 - 146,700
Pharma Reaserch Products 146,100 +5000 +3.54%

214450 Balance Sheet

 
Featured here, the Balance Sheet for Pharma Reaserch Products Co Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Current Assets 296195.03 256465.27 298691.27 271290.51
Cash and Short Term Investments 198022.06 160298.06 205130.15 191504.09
Cash - - - -
Cash & Equivalents 121609.62 67244.84 80252.49 68099.96
Short Term Investments 41161.6 56548.52 46724 36564
Total Receivables, Net 35907.55 35997.71 39249.83 34733.69
Accounts Receivables - Trade, Net 31798.01 31399.95 34408.71 31933.64
Total Inventory 51337.6 50232.37 49872.35 41135.57
Prepaid Expenses 1174.87 1191.22 1125.62 1387.99
Other Current Assets, Total 9752.94 8745.92 3313.33 2529.18
Total Assets - 535281.19 535094.03 503744.3
Property/Plant/Equipment, Total - Net - 123060.6 120788.57 118594.37
Property/Plant/Equipment, Total - Gross 161927.08 157139.31 153109.44 148941.77
Accumulated Depreciation, Total -36301.5 -34078.72 -32320.87 -30347.39
Goodwill, Net 11652.27 11652.27 13809.61 13809.61
Intangibles, Net 18746.51 18708.84 20896.88 21479.38
Long Term Investments 93042.72 96950.83 48440.59 45561.35
Note Receivable - Long Term 2352.42 3300.76 3554.71 1524
Other Long Term Assets, Total 20620.77 18415.47 20650.95 20933
Other Assets, Total 116189.6 127358.71 151916.06 145687.31
Total Current Liabilities 93326.4 65899.49 52505.95 49785.17
Accounts Payable 8989.7 2830.98 5769.22 8008.33
Payable/Accrued - - - -
Accrued Expenses 1358.53 974.34 1123.01 1157.39
Notes Payable/Short Term Debt 32900.17 32344.52 17382.88 17341.29
Current Port. of LT Debt/Capital Leases 1154.22 661.55 1011.46 1254.5
Other Current liabilities, Total 48923.78 29088.11 27219.38 22023.66
Total Liabilities 107060.95 73086.59 90173.89 88278.12
Total Long Term Debt 8177.47 1300.63 31811.15 32556.07
Long Term Debt 6789.31 970.72 31335.99 32069.85
Capital Lease Obligations 1388.16 329.91 475.16 486.22
Deferred Income Tax 2629.85 2794.21 3234.48 3403.37
Minority Interest 30046.77 29090.96 28840.72 27188.72
Other Liabilities, Total -60019.7 -58969.79 -59252.83 -41996.5
Total Equity 471658.97 462194.6 444920.14 415466.18
Redeemable Preferred Stock, Total 791.8 - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 5160.21 5160.21 5156.24 5148.28
Additional Paid-In Capital 175558.65 175427.9 174711.6 173427.68
Retained Earnings (Accumulated Deficit) 268340.76 260787.36 245422.59 218713.01
Treasury Stock - Common -4638.4 -4638.4 -4638.4 -4638.4
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 26445.95 25457.51 24268.12 22815.6
Total Liabilities & Shareholders' Equity - 535281.19 535094.03 503744.3
Total Common Shares Outstanding 10.2 10.2 10.19 10.26
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

214450 Comments

Write your thoughts about Pharma Reaserch Products Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email